Skip to main content

Align Technology Awards Funding to Universities Worldwide to Advance Orthodontic and Dental Research

$250,000 in Research Grants Awarded as Part of Annual Research Awards Program

TEMPE, Ariz., June 02, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of ten research grants under the company’s eleventh Annual Research Award Program.

The global interest in research to advance dental and orthodontic treatments continues to grow as evidenced by the increasing number of applications Align Technology receives each year from universities around the world. Since the program’s inception in 2010, Align has funded over $2.0 million in research awards that have led to advancements in digital orthodontics and digital dentistry.

“We are proud to support scientific research to further advance the study of dentistry and orthodontics, and congratulate this year’s group of research award winners,” said Dr. Mitra Derakhshan, vice president – Global Clinical, Align Technology. “These studies focus on work that can contribute to improvements in oral health care and orthodontic movement, and support Align’s purpose of transforming smiles and changing lives.”

The Americas research award recipients for 2021 are:

  • University of British Columbia (Vancouver, Canada) – Primary Investigator, Dr. Edwin H.K. Yen
  • University of Toronto (Toronto, Canada) – Primary Investigator, Dr. Anuradha Prakki
  • University of Toronto (Toronto, Canada) – Primary Investigator, Dr. Céline Lévesque
  • University at Buffalo (Buffalo, New York) – Primary Investigator, Dr. Pramod Philip

The European research award recipients for 2021 are:

  • The Hebrew University and Hadassah (Jerusalem, Israel) – Dr. Omer Fleissig
  • National and Kapodistrian University of Athens (Athens, Greece) – Primary Investigator, Dr. Iosif Sifakakis
  • University of Rome “Tor Vergata” (Rome, Italy) – Primary Investigator, Dr. Roberta Lione
  • Gothenburg University (Gothenburg, Sweden) – Primary Investigator, Anna Westerlund        

The Asia Pacific research award recipients for 2021 are:

  • Anhui Medical University (Hefei, China) – Primary Investigator, Dr. Xu Jianguang
  • Kunming Medical University (Yunnan, China) – Primary Investigator, Dr. Jiangtian Hu

The funded research studies cover a wide range of topics for projects seeking to better understand treatment in orthodontics and dentistry including, but not limited to:

  • Comparing the clinical performance of the index test in detecting supragingival interproximal caries
  • Investigating remineralizing properties of polyaspartic acid attached to a resin infiltrant
  • Evaluating the effects of mesenchymal stem cells transfer to periodontal ligament on the rate of orthodontic tooth movement
  • Role of adaptive immunity and B-cells in orthodontic tooth movement
  • Determining the effect of probiotics on oral health
  • Examining the effect of Class II elastics on the vertical dimension
  • Prevention and progression of caries with the addition of an active agent in aligners
  • Comparing the effectiveness of Invisalign mandibular advancement with incremental advancements versus single advancement
  • Demonstrating Invisalign® First treatment is effective in treating anterior crossbite

All award applications received were first reviewed and prioritized in a blind evaluation by an independent academic committee. The final recipients were then determined by Align Technology.

About Align Technology, Inc.

Align Technology designs, manufactures and offers the Invisalign system, the most advanced clear aligner system in the world, iTero intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 200 thousand doctor customers and is key to accessing Align’s 500 million consumer market opportunity worldwide. Align has helped doctors treat over 10.2 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit http://www.exocad.com.

Align TechnologyZeno Group
Madelyn HomickSarah Johnson
(408) 470-1180(828) 551-4201
mhomick@aligntech.comsarah.johnson@zenogroup.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.